从基因工程小C肽人胰岛素原类似物（B－R2－A）制备人胰岛素

以融合蛋白的形式,在Ｅ．ｃｏｌｉ中经温度诱导表达了小Ｃ肽人胰岛素原类似物（Ｂ－Ｒ２－Ａ）．表达的融合蛋白可占细胞总蛋白６８％．经磺酸解,及初步分离Ｓ－磺酸型融合蛋白,再经ＣＮＢｒ裂解后,进行还原重组,ＨＰＬＣ分离纯化等步骤,每升发酵液可得到Ｂ－Ｒ２－Ａ约５０ｍｇ。经酶促转化及ＤＥＡＥ－ＳｅｐｈａｄｅｘＡ－２５纯化,得重组人胰岛素约２０ｍｇ,其氨基酸组成与人胰岛素相同,并具有与猪胰岛素相同的生物活性．     

RGD肽与尿激酶B链融合蛋白原核重组表达质粒的构建,表达和？…

将化学合成的ＲＧＤ肽（Ａｒｇ－Ｇｌｙ－Ａｓｐ）编码寡核苷酸与尿激酶Ｂ链ｃＤＮＡ相连成为融合基因后,克隆至原核表达质粒ｐＢＶ２２０中,在ＰＲＰＬ自动子的作用下,经４２℃热诱导,在大肠杆菌ＤＨ５α中获得了融合基因的表达,其表达量占菌体总蛋白的９．２％,表达产物以无活性的包含体形式存在。经变复性处理得到纯化的融合基因的表达产物,经Ｗｅｓｔｅｒｎ－ｂｌｏｔｔｉｎｇ分析表明产物具有与天然尿激酶相似的抗原性,     

人组织性纤溶酶原激活物衍生物在大肠杆菌硫氧化还原蛋白融合表达系统中的

目的：克隆含ｔＰＡ中３５５个氨基酸密码子（１－３和１７６－５２７氨基酸）的ｃＤＮＡ序列（ｔＰＡ３５５）,将其在大肠杆菌融合蛋白表达系统中表达,并在体外复性使其具有激活纤溶酶原的生物活性。方法：采用ＲＴ－ＰＣＲ技术从人黑色素瘤细胞Ｂｏｗｅｓ中克隆出ｔＰＡ３５５ ｃＤＮＡ,然后在ｐＥＴ３２ａ（＋）ＢＬ２１（ＤＥ３）大肠杆菌表达系统中表达,将表达出的融合蛋白Ｔｒｘ－ｔＰＡ３５５（Ｔｈｉｏｒｅｄｏｘｉｎ,Ｔｒｘ）包涵体在体外进行变性、复性和纯化以使其具有激活纤溶酶原的生物活性。结果：测序结果表明本研究克隆的编码ｔＰＡ中３５５个氨基酸密码子的ｃＤＮＡ序列与美国专利（公开号：５,５８７,１５９）中对应的序列完全一致,将其在ｐＥＴ３２ａ（＋）／ＢＬ２１（ＤＥ３）大肠杆菌表达系统中表达可获得稳定表达的融合蛋白Ｔｒｘ－ｔＰＡ３５     

东亚钳蝎神经毒素在大肠杆菌中的表达

以山西风陵渡东亚钳蝎（ＢｕｔｈｕｓｍａｒｔｅｎｓｉＫａｒｓｃｈ）的尾腺总ＲＮＡ为模板,根据已知的蝎神经毒素保守氨基酸序列设计引物,利用ＰＣＲ技术,扩增并克隆了两个蝎神经毒素基因．序列分析表明,由两个基因导出的氨基酸序列（ＢｍＫＭｍ１和ＢｍＫＭｍ２）与已知的蝎神经毒素ＢｍＫⅠ、ＢｍＫⅡ、ＢｍＫⅢ、ＢｍＫＭ１、ＢｍＫＭ９有很高的同源性．将ＢｍＫＭｍ２基因重组到大肠杆菌分泌型表达载体ｐＥｘＳｅｃ１中进行表达．ＳＤＳ－ＰＡＧＥ证明表达产物被分泌到细胞周间质及培养液中．经ＩｇＧ－Ｓｅｐｈａｒｏｓｅ纯化后的蛋白质注射小白鼠表明表达产物有生物学活性     

Nm23-H1/NDPK-A基因在大肠杆菌中的高效表达及产物纯化的研究

利用聚合酶链反应（ＰＣＲ）技术扩增人二磷酸核苷激酶Ａ亚基（ＮＤＰＫ－Ａ）基因,即ｎｍ２３－Ｈ１／ＮＤＰＫ－Ｋ基因的编码序列,经序列分析后,定向克隆于表达质粒载体ｐＢＶ２２０,在大肠杆菌ＤＨ５α中高效表达出重组人ＮＤＰＫ－Ａ．表达产物为可溶性的非融合蛋白,占菌体总蛋白４２％．斑点ＥＬＩＳＡ法鉴定表明表达产物与ＮＤＰＫ－Ａ标准抗血清呈阳性反应．以ＤＥＡＥ纤维素弱阴离子交换层析、ＣｉｂａｃｒｏｎＢｌｕｅ染料亲和层析结合高效液相排阻色谱技术纯化ｒＮＤＰＫ－Ａ,得纯度为９６．７％的目标蛋白．以反相高效液相色谱法进行酶活性分析,表明纯化的ｒＮＤＰＫ－Ａ能催化ＡＴＰ＋ＵＤＰ＝ＡＤＰ＋ＵＴＰ的反应,比活性为８００Ｕ／ｍｇ蛋白．     

高效融合表达中载体蛋白对hIGF－Ⅰ免疫原性结构形成的影响

利用人工全合成人胰岛素样生长因子工（ｈＩＧＦ－Ｉ）基因,构建了分别以β－半乳糖苷醇（β－ｇａｌ）的三种即含５９０、３１０、２８０个氨基酸序列片段和一种以ＰｒｏｔｅｉｎＡ的Ｂ、Ｃ结构域（ＰＡＢＣ）为载体蛋白的融合型表达质粒,并在大肠杆菌中高效表达了以上各种ｈＩＧＦ－Ｉ的融合蛋白产物。通过对羟胺裂解前后的ｈＩＧＦ－Ｉ产物进行放射免疫结合测定分析,结果显示以β－Ｇａｌ６９０、３１０、２８０为载体蛋白,均严重影响与其融合的ｈＩＧＦ－Ｉ的免疫原性结构形成,但在ＰＡＢＣ－ｈＩＧＦ－Ｉ融合蛋白中,载体蛋白ＰＡＢＣ无明显的影响作用。这表明在高融合表达低分子量蛋白或肽段中,需选择适宜的载体蛋白,以利于目的产物的功能性结构形成。     

从基因工程小C肽人胰岛素原类似物（B—R2—A）制备人胰岛素

以融合蛋白的形式,在Ｅｃｏｌｉ中经温度诱导表达了小Ｃ肽人胰岛素原来似物（Ｂ－Ｒ２－Ａ）,表达的融合蛋白可占细胞总蛋白６８％。经磺酸解,及初步分离Ｓ－磺酸型融合蛋白,再经ＣＮＢｒ裂解后,进行还原重组,ＨＰＬＣ分离纯化等步骤,每升发酵液可得到Ｂ－Ｒ２－Ａ约５０ｍｇ。经酶促转化及ＤＥＡＥ－Ｓｅｐｈａｄｅｘ－Ａ２５纯化,得重组人胰岛素约２０ｍｇ,基氨基酸组成与人胰岛素相同,并具有与猪胰岛素相同的生物活性。     

两个东亚钳蝎抗哺乳动物神经毒素的cDNA序列

从我国山东东亚马氏钳蝎尾腺中分离纯化ｍＲＮＡ,经逆转录构建了ＢｍＫ蝎毒ｃＤＮＡ文库。利用ＰＣＲ扩增,筛选到两个抗哺乳动物毒素的ｃＤＮＡ基因,并测定了序列。这两个ｃＤＮＡ阅读框均为２５２ｂｐ组成,可翻译８４肽的毒素前体,包括Ｎ端１９个氨基酸组成的信号肽,６４个氨基酸残芭的成熟毒蛋白,以及Ｃ端一个额外的碱性氨基酸Ａｒｇ。其中由一ＣＤＮＡ所推导的氨基酸序列（ＢｍＫＭ１）一已知的天然毒素ＢｍＫ１蛋白序列完     

缩短的人巨噬细胞集落刺激因子（M－CSF）在大肠杆菌中的表达

本文用聚合酶链反应（ＰＣＲ）获得了一个缩短的人巨噬细胞集落刺激因子（编码３～１４９氨基酸）ｃＤＮＡ基因,并克隆在质粒ｐＥＴ３ｄ中,在Ｔ７启动子指导下,在大肠杆菌ＢＬ２１（ＤＥ３）ＬｙｓＥ中获得了和一个６组氨酸短肽标签的融合表达。重组的融合ｍ－ＣＳＦ表达量占菌体总蛋白的１２％,表达产物一部分以不溶性包涵体形式存在,另一部分则以可溶性蛋白存在。经过金属螫合亲和层析一步纯化,所得的融合（Ｈｉｓ）６－Ｍ－ＣＳＦ在还原型ＳＤＳ－ＰＡＧＥ上基本呈一条均一的蛋白质条带。     

萝卜抗真菌蛋白1（Rs—AFP1）在大肠杆菌中的融合表达及其对大丽轮 …

利用聚合酶链式反应（ＰＣＲ）获得了萝卜（Ｒａｑｈａｎｕｓ ｓａｔｉｖｕｓ Ｌ．）抗真菌蛋白１（Ｒｓ－ＡＦＰ１）基因编码区核苷酸序列。将整个阅读框架片段和云除了Ｎ－端信号肽序列的片段分别装入原核表达载体ｐＥＴ－３２ｇ（＋）中,在大肠杆菌中表达,发现带有信号 的Ｒｓ－ＡＦＰ１不能在大肠杆菌中表达,而当这一序列去除后,表达出约２７ｋＤ的Ｒｓ－ＡＦＰ１的融合蛋白。用凝血酶处理融合蛋白以云除Ｎ－端Ｈｉｓ．ｔ     

Met-Lys-双C肽人胰岛素原基因的构建表达及分离纯化

应用 Ｐ Ｃ Ｒ 定点突变方法构建编码 Ｍ ｅｔ Ｌｙｓ 双 Ｃ 肽人胰岛素原基因,并在大肠杆菌中以包含体方式获得表达 表达产物经还原、重组、 Ｓｅｐｈａｄｅｘ Ｇ ７５ 分离纯化,获得 Ｍ ｅｔ Ｌｙｓ 双 Ｃ 肽人胰岛素原,经胰蛋白酶与羧肽酶 Ｂ的酶解, Ｒｅｓｏｕｒｃｅ Ｔ Ｍ Ｑ 阴离子交换柱层析分离制备得人胰岛素,其放免活性、受体结合活性均与猪胰岛素相同      

hGH-双精氨酸C肽人胰岛素原基因的克隆表达及纯化研究

旨在提高基因重组人胰岛素在大肠杆菌中表达的稳定性及表达包涵体蛋白的复性水平.在人胰岛素原N端前融合人生长素N端的一段序列来充当前导肽,同时将C肽设计为两个精氨酸,分10段合成长链寡核苷酸链,利用重叠延伸PCR技术(SOE PCR)扩增得到该基因片段.与表达载体PET-30a连接,转化E.coli BL21(DE3),IPTG诱导表达.表达的融合蛋白采用Ni-NTA亲和层析纯化,纯化后的蛋白经复性、冻干等步骤后用胰蛋白酶,羧肽酶B双酶切再过DEAE Sepharose Fast Flow阴离子交换柱,收集洗脱峰.对制备所得的胰岛素用SDS-PAGE,Western blot进行性质鉴定,及皮下注射小鼠测定生物活性.结果显示,目的蛋白在大肠杆菌BL21(DE3)中得到了表达,表达产物以不溶性包涵体形式纯在,约占大肠杆菌总蛋白的30%.经Ni-NTA亲和层析得到的重组蛋白纯度为85%,DEAE Sepharose Fast Flow阴离子交换纯化得到单组分胰岛素.Western Blot显示制备所得的胰岛素具有胰岛素免疫原性,皮下给药注射小鼠活性测定表明具有明显的降血糖活性.获得了一种高效生产基因重组人胰岛素的方法,为研究胰岛素类似物奠定了前期基础同时也为今后探索胰岛素的非注射给药途径提供了原料.     

去B链羧端七肽人胰岛素的分离纯化及性质研究

在大肠杆菌温度诱导体系中以非融合方式进行去Ｂ链羧端七肽人胰岛素原基因的表达,获得去Ｂ链羧端七肽人胰岛素原,表达产物占细胞总蛋白量的１３％,表达产物经ＳｅｐｈａｄｅｘＧ－５０柱层析分离及胰蛋白酶和羧肽酶Ｂ的酶促转化等步骤,可得到纯度达９４％以上的去Ｂ链羧端七肽人胰岛素,其氨基酸组成与预期值相符,受体活性是标准猪胰岛素的１％．     

Synthesis of human proinsulin in Escherichia coli cells

Expression of the synthetic gene for human proinsulin in E. coli has been investigated. The proinsulin gene has been expressed directly under the control of a synthetic promoter of phage fd DNA and a promoter of tryptophan operon, or using fusions with fragments of some bacterial proteins. These fusions gave insoluble polypeptide products amounting to 20-30% of total cellular protein. The scheme for isolating proinsulin from bacterial cells was developed. Proinsulin was cleaved from leader polypeptides by treatment with cyanogen bromide and converted into human insulin.     

The design of a simple competitive ELISA using human proinsulin-alkaline phosphatase conjugates prepared by gene fusion

The gene encoding human proinsulin has been fused in-frame with the E. coli alkaline phosphatase gene (pho A) (EC 3.1.3.1). Two constructions are described. One construction consists of the entire proinsulin gene fused to the 5'-terminal end of pho A. In the other construction a 42 base pair DNA fragment has been deleted from the 3'-terminal end of the proinsulin gene. The two purified fusion proteins are enzymatically active showing a specific activity of 10-15 U/mg and 18-25 U/mg, respectively. The first construction exhibited insulin antigenicity and was used to design a simple competitive ELISA for insulin. The lower detection limit was found to be at least 2.5 ng/ml. Both fusion proteins were also shown to have potential for use in a competitive ELISA for proinsulin.     

去B链羧端三肽人胰岛素的分离纯化及其性质研究

将去Ｂ链羧端三肽人胰岛素原基因克隆到表达质粒ｐＢＶ２２０上,在大肠杆菌系统中经温度诱导表达,表达产物占细胞总蛋白量的１２％,表达产物经ＳｅｐｈａｄｅｘＧ－５０柱层析分离以及胰蛋白酶和羧肽酶Ｂ的酶促转化等步骤,可得到去Ｂ链羧端三肽人胰岛素,其纯度达９３％,其氨基酸组成与预期值相符,但其受体结合活性仅是标准猪胰岛素的４５％．     

(A-C-B) human proinsulin, a novel insulin agonist and intermediate in the synthesis of biosynthetic human insulin.

The hormone insulin is synthesized in the beta cell of the pancreas as the precursor, proinsulin, where the carboxyl terminus of the B-chain is connected to the amino terminus of the A-chain by a connecting or C-peptide. Proinsulin is a weak insulin agonist that possesses a longer in vivo half-life than does insulin. A form of proinsulin clipped at the Arg65-Gly66 bond has been shown to be more potent than the parent molecule with protracted in vivo activity, presumably as a result of freeing the amino terminal residue of the A-chain. To generate a more active proinsulin-like molecule, we have constructed an "inverted" proinsulin molecule where the carboxyl terminus of the A-chain is connected to the amino terminus of the B-chain by the C-peptide, leaving the critical Gly1 residue free. Transformation of Escherichia coli with a plasmid coding for A-C-B human proinsulin led to the stable production of the protein. By a process of cell disruption, sulfitolysis, anion-exchange chromatography, refolding, and reversed-phase high-performance liquid chromatography, two forms of the inverted proinsulin differing at their amino termini as Gly1 and Met0-Gly1 were identified and purified to homogeneity. Both proteins were shown by a number of analytical techniques to be of the inverted sequence, with insulin-like disulfide bonding. Biological analyses by in vitro techniques revealed A-C-B human proinsulin to be intermediate in potency when compared to human insulin and proinsulin. The time to maximal lowering of blood glucose in the fasted normal rat appeared comparable to that of proinsulin. Additionally, we were able to generate fully active, native insulin from A-C-B human proinsulin by proteolytic transformation. The results of this study lend themselves to the generation of novel insulin-like peptides while providing a simplified route to the biosynthetic production of insulin.     

Chelating peptide-immobilized metal ion affinity chromatography. A new concept in affinity chromatography for recombinant proteins

We report our experimental results supporting the hypothesis that a specific metal-chelating peptide (CP) on the NH2 terminus of a protein can be used to purify that protein using immobilized metal ion affinity chromatography (IMAC). The potential utility of this approach resides with recombinant proteins since the nucleotide sequence that codes for the protein can be extended to include codons for the chelating peptide and thereby generate the gene for a chimeric CP-protein that can be cloned, expressed, and affinity-purified with immobilized metal ions. The chelating peptide purification handle could then be removed chemically or enzymatically after purification has been achieved to generate a protein with the natural amino acid sequence. The feasibility of using a chelating peptide as a purification handle has been demonstrated using a leuteinizing hormone-releasing hormone (LHRH) analog, 2-10 LHRH, which contains the previously identified chelating peptide, His-Trp, on the NH2 terminus. 2-10 LHRH had a high affinity for a Ni(II) IMAC column due to the NH2-terminal dipeptide sequence His-Trp, forming a coordination complex with Ni(II), whereas the controls, 3-10 LHRH and 4-10 LHRH, lacking the CP sequence, did not bind. Furthermore, 2-10 LHRH could be purified from a mixture of histidine-containing peptides on a Ni(II) IMAC column in one step. His-Trp proinsulin was used as a model of a recombinant CP-protein. The S-sulfonates of His-Trp-proinsulin and proinsulin were isolated from Escherichia coli engineered to overproduce these proteins as trpLE' fusion proteins. His-Trp-proinsulin(SSO3-)6 had a higher affinity for immobilized Ni(II) than proinsulin (SSO3-)6. Both proteins were eluted by decreasing the pH or by introducing a displacing ligand into the buffer. Ni(II) eluted from the column with much higher concentrations of displacing ligand than the proteins.     

A new secreted insect protein belonging to the immunoglobulin superfamily binds insulin and related peptides and inhibits their activities

Insulin and related peptides are key hormones for the regulation of growth and metabolism. Here we describe a novel high affinity insulin-related peptide-binding protein (IBP) secreted from cells of the insect Spodoptera frugiperda. This IBP is composed of two Ig-like C2 domains, has a molecular mass of 27 kDa, binds human insulin with an affinity of 70 pm, and inhibits insulin signaling through the insulin receptor. The binding protein also binds insulin-like growth factors I and II, proinsulin, mini-proinsulin, and an insulin analog lacking the last 8 amino acids of the B-chain (des-octa peptide insulin) with high affinity, whereas an insulin analog with a Asp-B10 mutation bound with only 1% of the affinity of human insulin. This binding profile suggests that IBP recognizes a region that is highly conserved in the insulin superfamily but distinct from the classical insulin receptor binding site. The closest homologue of the Spodoptera frugiperda binding protein is the essential gene product IMP-L2, found in Drosophila, where it is implicated in neural and ectodermal development (Garbe, J. C., Yang, E., and Fristrom, J. W. (1993) Development 119, 1237-1250). Here we show that the IMP-L2 protein also binds insulin and related peptides, offering a possible functional explanation to the IMP-L2 null lethality.